Stoke Therapeutics Inc Stock
Price
Target price
?
?
0.040%
0.01
0.040%
€33.82
08:12 / Frankfurt
WKN: A2PLTL / Symbol: STOK / Name: Stoke Therapeutics / Stock / Biotechnology & Medical Research / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Stoke Therapeutics Inc Stock
There is nearly no change for the Stoke Therapeutics Inc stock today. Compared to yesterday it only changed by €0.010.
With 19 Buy predictions and not the single Sell prediction the community is currently very high on Stoke Therapeutics Inc.
With a target price of 33 € there is a positive potential of 23.97% for Stoke Therapeutics Inc compared to the current price of 26.62 €.
So far the community has only identified positive things for Stoke Therapeutics Inc stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Stoke Therapeutics Inc in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Stoke Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Stoke Therapeutics Inc | 0.040% | -1.844% | 5.679% | 77.400% | -1.444% | 456.695% | 20.955% |
| Personalis Inc | 0.770% | 2.248% | -9.150% | 217.835% | 85.608% | 651.351% | -19.342% |
| Immuron | -3.230% | 2.762% | -9.709% | -35.862% | 37.778% | -44.311% | -75.654% |
Comments
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Guggenheim. They now have a $60.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its price target raised by Wedbush from $38.00 to $40.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for STOK provided by MarketBeat
Stoke Therapeutics (STOK) had its "buy" rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
Show more
Ratings data for STOK provided by MarketBeat
